About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. BPX-501 is an adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation. The Company's CID-based technologies include CaspaCIDe, CIDeCAR and GoCAR-T.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: BLCM
- Previous Close: $13.62
- 50 Day Moving Average: $13.23
- 200 Day Moving Average: $16.93
- 52-Week Range: $7.24 - $23.11
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.53
- P/E Growth: 0.00
- Market Cap: $352.37M
- Outstanding Shares: 27,105,000
- Beta: 1.48
- Net Margins: -19,399.12%
- Return on Equity: -49.65%
- Return on Assets: -42.92%
Companies Related to Bellicum Pharmaceuticals:
- Debt-to-Equity Ratio: 0.18%
- Current Ratio: 12.41%
- Quick Ratio: 12.41%
What is Bellicum Pharmaceuticals' stock symbol?
Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."
Where is Bellicum Pharmaceuticals' stock going? Where will Bellicum Pharmaceuticals' stock price be in 2017?
7 brokerages have issued twelve-month target prices for Bellicum Pharmaceuticals' stock. Their predictions range from $20.00 to $32.00. On average, they anticipate Bellicum Pharmaceuticals' share price to reach $27.00 in the next year.
When will Bellicum Pharmaceuticals announce their earnings?
Bellicum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
Who owns Bellicum Pharmaceuticals stock?
Bellicum Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (12.67%), Franklin Resources Inc. (2.40%), State Street Corp (1.20%), Eventide Asset Management LLC (0.92%), Renaissance Technologies LLC (0.31%) and Fred Alger Management Inc. (0.17%). Company insiders that own Bellicum Pharmaceuticals stock include Alan A Musso, Annemarie Moseley, David M Spencer, Ken Moseley, Kevin M Slawin and Thomas J Farrell.
Who sold Bellicum Pharmaceuticals stock? Who is selling Bellicum Pharmaceuticals stock?
Bellicum Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., FMR LLC and Fred Alger Management Inc.. Company insiders that have sold Bellicum Pharmaceuticals stock in the last year include Alan A Musso, Annemarie Moseley, David M Spencer, Ken Moseley and Kevin M Slawin.
Who bought Bellicum Pharmaceuticals stock? Who is buying Bellicum Pharmaceuticals stock?
Bellicum Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Renaissance Technologies LLC, Allianz Asset Management AG and State Street Corp.
How do I buy Bellicum Pharmaceuticals stock?
Shares of Bellicum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Bellicum Pharmaceuticals stock cost?
One share of Bellicum Pharmaceuticals stock can currently be purchased for approximately $13.39.